Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
6.38
-0.25 (-3.77%)
Mar 19, 2026, 4:00 PM EDT - Market closed

Silence Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
301287325688548715
Market Cap Growth
34.91%-11.61%-52.78%25.56%-23.35%17.04%
Enterprise Value
216.4202.07177.57619.46461.96615.56
Last Close Price
6.386.086.8817.3715.2523.89
PE Ratio
--3.22-6.95-11.82-9.78-13.27
PS Ratio
539.09513.747.5121.3025.3142.60
PB Ratio
4.840.240.29-31.7020.5262.03
P/TBV Ratio
0.250.240.29-29.6818.39-
P/FCF Ratio
--4.61-4.79-13.72-9.5896.24
P/OCF Ratio
--4.61-4.80-13.74-9.6177.70
EV/Sales Ratio
387.12361.484.1019.1821.3336.67
EV/EBITDA Ratio
--2.23-2.83-9.91-7.64-10.03
EV/EBIT Ratio
--2.22-2.80-9.81-7.57-9.94
EV/FCF Ratio
--3.24-2.62-12.35-8.0782.86
Debt / Equity Ratio
-000.00--
Debt / EBITDA Ratio
0.000.000.00-0.01-0.010.00
Debt / FCF Ratio
0.000.000.00-0.01-0.010.03
Net Debt / Equity Ratio
-0.07-0.07-0.133.15-3.20-8.61
Net Debt / EBITDA Ratio
0.940.942.351.101.421.62
Net Debt / FCF Ratio
0.831.362.171.371.50-13.36
Asset Turnover
0.000.000.270.260.170.14
Quick Ratio
7.877.8710.274.053.965.33
Current Ratio
8.728.7211.144.564.415.69
Return on Equity (ROE)
-90.27%-90.27%-51.07%-253.77%--
Return on Assets (ROA)
-54.52%-54.52%-38.57%-43.53%-46.28%-43.00%
Return on Invested Capital (ROIC)
-253.40%-253.40%-168.49%-170.96%-269.00%-149.55%
Return on Capital Employed (ROCE)
-59.99%-59.99%-44.81%-63.04%-57.30%-64.48%
Earnings Yield
-29.40%-31.09%-14.39%-8.46%-10.23%-7.53%
FCF Yield
-20.68%-21.70%-20.88%-7.29%-10.44%1.04%
Buyback Yield / Dilution
-0.01%-0.01%-43.73%-4.50%-9.59%-5.85%
Updated Mar 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q